SACS rabbit pAb
ENT-A10699
Description
| REF | ENT-A10699 |
|---|---|
| Category | Antibody Polyclonal |
| Description | SACS rabbit pAb |
| Source | Rabbit |
| Applications | IHC;IF |
| Reactivity | Human;Mouse |
| Reactivity | Human;Mouse |
| Dilution | IHC-p 1:50-300 |
| Immunogen | Synthesized peptide derived from human protein . at AA range: 4291-4340 |
| Storage Stability | -20°C/1 year |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1 mg/ml |
| Observed Band KD | 503kD |
| Human Gene ID | 26278 |
| Human Swiss Prot Nº | Q9NZJ4 |
| Subcellular Location | Cytoplasm . Predominantly cytoplasmic, a small portion is present in the nucleus and also shows a partial mitochondrial overlap with the mitochondrial marker Hsp60. |
Other Name:
Background: This gene encodes the sacsin protein, which includes a UbL domain at the N-terminus, a DnaJ domain, and a HEPN domain at the C-terminus. The gene is highly expressed in the central nervous system, also found in skin, skeletal muscles and at low levels in the pancreas. This gene includes a very large exon spanning more than 12.8 kb. Mutations in this gene result in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), a neurodegenerative disorder characterized by early-onset cerebellar ataxia with spasticity and peripheral neuropathy. The authors of a publication on the effects of siRNA-mediated sacsin knockdown concluded that sacsin protects against mutant ataxin-1 and suggest that “the large multi-domain sacsin protein is able to recruit Hsp70 chaperone action and has the potential to regulate the effects of other ataxia proteins” (Parfitt et al., PubMed: 19208651).
